Pharmaceutical Technology

JULY 14, 2025

The company is confident that these concerns, which pertain to facilities and processes rather than product quality, can be promptly addressed. While the CRL will delay the potential approval of UX111 to 2026, we are working with urgency to respond and resubmit.” Efforts are underway to work with the FDA to resolve them.

Insurance Coverage and Processing

Pharmaceutical Technology

JULY 25, 2025

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. GlobalData is the parent company of Clinical Trials Arena. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Insurance Coverage and Processing

Beckers Hospital Review

JULY 17, 2025

to find out one specific way each of them has redesigned a process or care model in the past year to serve more patients — without adding staff. To meet this challenge, Infirmary Health redesigned its clinical documentation integrity process without adding staff. Alaska Mikal Canfield.

Insurance Coverage and Processing

Pharmaceutical Technology

JULY 30, 2025

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. His exit raises critical questions: which evidence standards will prevail: traditional or accelerated?” commented Cynthia Pussinen, CEO of Owl Bio Advisors, a life sciences consultancy group. Give your business an edge with our leading industry insights.

Insurance Coverage and Processing

Beckers Hospital Review

JULY 1, 2025

Health insurers covering more than 250 million Americans have unveiled a sweeping plan to streamline and reduce prior authorization requirements — a long-standing source of frustration and burnout for providers and patients. I don’t believe that it will substantially decrease denials but might just speed up the denial process.

Insurance Coverage and Processing

Pharmaceutical Technology

JULY 17, 2025

Sarepta Therapeutics is set to cut 500 jobs as part of its restructuring and pipeline prioritisation plan, which is expected to result in annual cash cost savings of $120m in 2026. With its pipeline reprioritisation, the company anticipates delivering $300m in annual non-personnel cost savings from 2026.

Insurance Coverage and Processing

Pharmaceutical Technology

JUNE 13, 2025

By GlobalData Learn more about Strategic Intelligence Moderna said it plans to have mRESVIA available for both both younger adults and older adults in the US in time for the 2025-2026 respiratory virus season. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink.

Vaccines

Integra X Files

MAY 22, 2023

Prior authorization has been popular with the insurance industry because it works. This is known as the sentinel effect, and in the initial stages, providers accommodated the process without much complaint. The health insurance industry didn’t have many other tools to suppress demand, so it went with the sentinel effect by default.

Insurance Coverage and Processing

Putting Patients First Blog

JANUARY 16, 2024

The NBPP is a set of rules and guidelines issued annually by CMS that outline the policies and standards for health insurance plans and issuers, primarily focusing on the Health Insurance Marketplace under the Affordable Care Act. These are the rules for the federal health insurance marketplace for the coming year.

Insurance Coverage and Processing

Putting Patients First Blog

JULY 2, 2024

We believe that patient-centric engagement is essential to ensure that the negotiation process leads to outcomes that genuinely benefit patients. 1 And we appreciated CMS’ thorough responses to comments for IPAY 2026 and hope the Agency will replicate this for this comment opportunity.

Drug Pricing

Putting Patients First Blog

JANUARY 27, 2025

Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs. Below, we provide detailed comments and recommendations on key provisions of the proposed rule.

Insurance Coverage and Processing

Putting Patients First Blog

SEPTEMBER 3, 2024

The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.

Drug Pricing

Putting Patients First Blog

JANUARY 10, 2024

Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.

Insurance Coverage and Processing

Putting Patients First Blog

MARCH 4, 2024

Under the new Manufacturer Discount Program, manufacturers will be required to provide discounts on applicable drugs during the initial coverage phase and catastrophic phase of the defined standard Part D drug benefit.

Insurance Coverage and Processing

Big Molecule Watch

AUGUST 25, 2023

Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to determine, and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.

Drug Pricing

Express Pharma

JANUARY 12, 2024

. – Considering that the government promotes companies to “Make in India”, we request that the time limit for commencing manufacturing or production be further extended to 31 March 2026. Therefore, the sunset period should be extended for borrowings in foreign currency up to 31 March 2026; this would support the vision of “Make in India”.

Insurance Coverage and Processing

Putting Patients First Blog

NOVEMBER 12, 2024

General Support for CMS Proposals The NHC commends CMS for its ongoing commitment to advancing health equity, improving access to care, ensuring program integrity, and maintaining affordability through Marketplace coverage. Copay Assistance and Drug Coverage in Large Group Plans Accumulator Adjustment Programs and Cost Sharing.

Insurance Coverage and Processing

Putting Patients First Blog

FEBRUARY 11, 2025

Overarching Comments The NHC acknowledges CMS efforts to implement meaningful policy updates in CY 2026 to advance equity, affordability, and access to high-value care for Medicare beneficiaries. 3 Establishing a feedback loop with stakeholders during this monitoring process will provide additional safeguards against adverse effects.

Insurance Coverage and Processing